Drug intelligence / Profile preview

GS-1291269

Development stage: Unknown
Lead developer: Gilead Sciences
Modality: Small Molecules

Overview

GS-1291269: sourced facts only. name: "Herein, we describe the discovery of GS-1291269, a potent, neutral KHK inhibitor." [PMID:41433313]; target: "Herein, we describe the discovery of GS-1291269, a potent, neutral KHK inhibitor." [PMID:41433313]; developer: "Gilead Sciences, Inc., Foster City, California 94404, United States." [PMID:41433313]; modality: "Herein, we describe the discovery of GS-1291269, a potent, neutral KHK inhibitor." [PMID:41433313]; stage: "Furthermore, GS-1291269 demonstrated liver and kidney fructose-1-phosphate (F1P) reduction in a fructose challenge model in rats." [PMID:41433313]

Targets

KHK (Ketohexokinase)

Beyond the preview

Go deeper on GS-1291269.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GS-1291269.